Drugs / Tretinoin
Tretinoin
also known as
all-trans retinoic acid · ATRA · VESANOID · Atralin · RETIN-A · RETIN-A MICRO · Altreno · liposomal tretinoin · +12 more
targets CYP26A1, HOXA3, HOXA4, HOXA5, NPM1, PBX3, PML, RARA via activation
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | VESANOID | — | 2023-02-21 | fda.gov ↗ |
| Label expansion | US (FDA) | RETIN-A-MICRO | — | 2002-05-10 | fda.gov ↗ |
| Label expansion | US (FDA) | RENOVA | — | 2000-08-01 | fda.gov ↗ |
| Approved | US (FDA) | RETIN-A | — | 1971-10-20 | fda.gov ↗ |
Trials 171 · started per year
today
US approved 1971
1
2
1
2
1
1
3
7
3
6
3
5
8
6
10
3
8
3
4
3
9
4
8
3
8
13
9
7
3
9
11
7
19711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials | ||||||
| Phase 0 | NCT05553782 | Nov 2023 → Apr 2029 expected | head and neck squamous cell carcinoma, salivary gland adenoid cystic carcinoma | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT05482451 | Mar 2021 → Feb 2025 overdue | — | China Medical University Hospital | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04883736 | Aug 2020 → Apr 2021 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 0 | NCT04724473 | Dec 2019 → Nov 2020 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 0 | NCT03427554 | Aug 2017 → Jan 2018 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 0 | NCT02620813 | Oct 2015 → Oct 2017 | acne | University of California, Davis | Completed | No outcome recorded |
| Phase 0 | NCT02410980 | Aug 2015 → Dec 2016 | collagenopathy | University of California, Irvine | Completed | No outcome recorded |
| Phase 124 trials | ||||||
| Phase 1 | NCT07842887 | Oct 2026 → Oct 2028 expected | non-small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07348107 | Feb 2026 → Mar 2027 expected | pancreatic ductal adenocarcinoma | Daniel Breadner | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07469228 | Aug → Dec 2025 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05388487 | Feb 2022 → Apr 2025 | cancer | HighField Biopharmaceuticals Corporation | Unknown | No outcome recorded |
| Phase 1 | NCT04919369 | Oct 2021 → Sep 2025 | non-small cell lung carcinoma | Dwight Owen | Completed | No outcome recorded |
| Phase 1 | NCT05386823 | Mar → Jul 2021 | — | HighField Biopharmaceuticals Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03878524 | Apr → Dec 2020 | acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, castration-resistant prostate carcinoma +14 | OHSU Knight Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04282668 | Mar 2020 → Feb 2024 | acute myeloid leukemia | Taiho Oncology, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT05297123 | Feb 2019 → Dec 2023 | acute myeloid leukemia | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 1 | NCT02850003 | Jun → Oct 2016 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03307148 | Jan 2016 → Mar 2019 | pancreatic adenocarcinoma | Barts & The London NHS Trust | Completed | No outcome recorded |
| Phase 1 | NCT02401295 | May → Aug 2015 | plasma cell myeloma | University of Iowa | Completed | No outcome recorded |
| Phase 1 | NCT02273102 | Mar 2015 → Nov 2018 | acute myeloid leukemia, myelodysplastic syndrome | University of Miami | Completed | No outcome recorded |
| Phase 1 | NCT02177812 | Aug 2014 → Dec 2017 | acute myeloid leukemia | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT02849860 | Feb 2014 → Sep 2016 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01985477 | Dec 2013 → Sep 2015 | plasma cell myeloma | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01820624 | Apr 2013 → Oct 2015 | acute erythroid leukemia, acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +7 | Paolo Caimi, MD | Completed | No outcome recorded |
| Phase 1 | NCT01456468 | Oct 2011 → Jun 2014 | primary sclerosing cholangitis | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT00892190 | Apr 2011 → Jan 2016 | acute myeloid leukemia, myelodysplastic syndrome | University of Pittsburgh | Completed | No outcome recorded |
| Phase 1 | NCT01929278 | Dec 2008 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 1 | NCT01915758 | Nov 2008 → Feb 2009 | acne | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00603772 | Jan → Mar 2008 | — | Coria Laboratories, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00400556 | Mar → May 2005 | plasma cell myeloma, primary cutaneous lymphoma | Peter MacCallum Cancer Centre, Australia | Completed | No outcome recorded |
| Phase 1 | NCT00006239 | Dec 2000 → Feb 2005 | leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1/218 trials | ||||||
| Phase 1/2 | NCT07848568 | Dec 2026 → Jun 2037 expected | posterior fossa ependymoma | Children's Oncology Group | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06536413 | Jul 2024 → Jul 2029 expected | plasma cell myeloma | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06439888 | Jul 2024 → Sep 2026 overdue | cancer | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05497310 | Jul 2022 → Jun 2025 | acute promyelocytic leukemia | Hospital Universitario Dr. Jose E. Gonzalez | Unknown | No outcome recorded |
| Phase 1/2 | NCT04305054 | Jul 2020 → May 2026 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04305041 | Jun 2020 → Aug 2025 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04303169 | Jun 2020 → Sep 2025 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04118296 | Oct → Nov 2019 | acne | Sukma Skin Treatment | Completed | No outcome recorded |
| Phase 1/2 | NCT03200847 | Oct 2017 → Jul 2022 | melanoma | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1/2 | NCT03259516 | May 2017 → Dec 2018 | myelodysplastic syndrome | St. Petersburg State Pavlov Medical University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03031249 | Feb 2017 → May 2026 overdue | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT02842827 | Oct 2016 → Oct 2018 | acute myeloid leukemia, myelodysplastic syndrome | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | Completed | No outcome recorded |
| Phase 1/2 | NCT02261779 | Sep 2014 → Sep 2017 | acute myeloid leukemia | Martin-Luther-University Halle-Wittenberg | Unknown | No outcome recorded |
| Phase 1/2 | NCT01369368 | Aug 2013 → Oct 2017 | acute myeloid leukemia | University of Bergen | Unknown | No outcome recorded |
| Phase 1/2 | NCT00995332 | Sep 2009 → Feb 2013 | acute myeloid leukemia | University of Bergen | Completed | No outcome recorded |
| Phase 1/2 | NCT00382200 | Jul 2006 → Jan 2023 | myelodysplastic syndrome | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00175812 | Nov 2004 → May 2008 | acute myeloid leukemia | University of Bergen | Completed | No outcome recorded |
| Phase 1/2 | NCT00006220 | Jun 1999 → Nov 2000 | leukemia, myelodysplastic syndrome, plasma cell neoplasm | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 258 trials · 2 met primary | ||||||
| Phase 2 | NCT07355855 | Jan 2026 → Jan 2029 expected | rhabdomyosarcoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07586826 | Dec 2025 → Oct 2027 expected | breast cancer, cervical cancer, fallopian tube cancer, non-small cell lung carcinoma +3 | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07586813 | Dec 2025 → Oct 2027 expected | colorectal cancer, malignant pancreatic neoplasm, thrombocytopenia | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06528769 | Sep 2025 → Dec 2027 expected | leiomyosarcoma | Gabriel Tinoco | Recruiting | No outcome recorded |
| Phase 2 | NCT07079696 | Sep 2025 → Jan 2027 expected | 15q11q13 microduplication syndrome, autism spectrum disorder | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06358677 | Feb 2025 → Jul 2027 expected | metastatic neoplasm | University of Utah | Recruiting | No outcome recorded |
| Phase 2 | NCT06646666 | Dec 2024 → Jun 2027 expected | B-cell non-Hodgkin lymphoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06703047 | Nov 2024 → Nov 2029 expected | esophageal squamous cell carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06484920 | Nov 2024 → Dec 2027 expected | B-cell non-Hodgkin lymphoma, Hodgkins lymphoma | Rita Assi | Recruiting | No outcome recorded |
| Phase 2 | NCT06636981 | Nov 2024 → Sep 2029 expected | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05999812 | Dec 2023 → Oct 2026 expected | colorectal cancer | University of Texas Southwestern Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06158412 | Nov 2023 → Dec 2025 overdue | plasma cell myeloma | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
| Phase 2 | NCT05345002 | Nov 2022 → Jun 2027 expected | astrocytoma (excluding glioblastoma), oligodendroglioma | Stephen Bagley, MD, MSCE | Recruiting | No outcome recorded |
| Phase 2 | NCT04700176 | May 2022 → Nov 2023 | plasma cell myeloma | Hackensack Meridian Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05077813 | Dec 2021 → Feb 2022 | tuberculosis | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 2 | NCT04618328 | Nov 2020 → Oct 2021 | autoimmune thrombocytopenia | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04568096 | Nov → Dec 2020 | lung disorder | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 2 | NCT06728631 | Jun 2020 → Dec 2023 overdue | oral cavity cancer, preneoplastic lesion | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04433169 | Jun 2020 → Dec 2022 | adenoid cystic carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Unknown | No outcome recorded |
| Phase 2 | NCT04241276 | Apr 2020 → Jun 2028 expected | malignant pancreatic neoplasm | Queen Mary University of London | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04217148 | Jan → Jun 2020 | autoimmune thrombocytopenia | Peking University People's Hospital | Completed | Met primary |
| Phase 2 | NCT04793919 | Oct 2019 → Oct 2025 overdue | acute promyelocytic leukemia | Italian Association of Pediatric Hematology and Oncology | Recruiting | No outcome recorded |
| Phase 2 | NCT03999684 | Aug 2019 → Apr 2020 | adenoid cystic carcinoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT04113863 | Jun 2019 → Jan 2025 | breast neoplasm | Mario Negri Institute for Pharmacological Research | Terminated | No outcome recorded |
| Phase 2 | NCT03572387 | Aug 2018 → Jun 2022 | prostate cancer | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT03359174 | May 2018 → Dec 2020 | primary sclerosing cholangitis | Yale University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03304288 | Oct 2017 → Jan 2021 | autoimmune thrombocytopenia | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03356080 | Jul 2017 → Jul 2019 | acute myeloid leukemia, myelodysplastic syndrome | Shanghai Tong Ren Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02942758 | Apr 2017 → Mar 2020 | acute myeloid leukemia | University Hospital Regensburg | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02788201 | Mar 2017 → Oct 2019 | urinary bladder cancer, urothelial carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02403778 | Dec 2015 → Aug 2018 | melanoma | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2 | NCT01667263 | Jun 2012 → Jul 2016 | autoimmune thrombocytopenia | Peking University People's Hospital | Completed | Met primary |
| Phase 2 | NCT01275274 | Jan 2012 → Dec 2013 | anti-neutrophil cytoplasmic antibody-associated vasculitis | University of North Carolina, Chapel Hill | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01409161 | Oct 2011 → Dec 2027 expected | acute promyelocytic leukemia | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT00867672 | Aug 2011 → Feb 2015 | acute myeloid leukemia | University Hospital Freiburg | Completed | Mixed |
| Phase 2 | NCT01404949 | Jul 2011 → Feb 2021 | acute promyelocytic leukemia | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00975312 | Aug → Nov 2008 | lentigo | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 2 | NCT00551460 | Nov 2007 → Jun 2017 | leukemia | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00617409 | Oct 2007 → Sep 2015 | small cell lung carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00528450 | Sep 2007 → Jan 2011 | leukemia | Memorial Sloan Kettering Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01048645 | Sep 2007 → Dec 2008 | non-small cell lung carcinoma | National Institute of Cancerology | Completed | No outcome recorded |
| Phase 2 | NCT00439673 | May 2007 → Jul 2010 | myelodysplastic syndrome | GIMEMA Foundation | Completed | No outcome recorded |
| Phase 2 | NCT00413166 | Dec 2006 → Feb 2016 | acute promyelocytic leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00601796 | Oct 2006 → Jun 2012 | lung cancer | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00326170 | Jul 2005 → Jul 2007 | acute myeloid leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00437450 | Oct 2004 → Sep 2005 | myelodysplastic syndrome | Groupe Francophone des Myelodysplasies | Unknown | No outcome recorded |
| Phase 2 | NCT00143975 | Jun 2004 → Jul 2007 | acute myeloid leukemia | University of Ulm | Completed | No outcome recorded |
| Phase 2 | NCT00016159 | Nov 2000 → Mar 2007 | leukemia | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01064570 | May 2000 → ? | acute promyelocytic leukemia | GIMEMA Foundation | Unknown | No outcome recorded |
| Phase 2 | NCT00000621 | Sep 1999 → Dec 2004 | pulmonary emphysema | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00005969 | Sep 1999 → Jan 2001 | lymphoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT00003601 | Feb 1999 → Mar 2000 | cutaneous melanoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00003656 | Jan 1999 → May 2008 | kidney cancer | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 2 | NCT00005825 | Sep 1998 → ? | lung cancer | Raghu Nandan, M.D., Inc | Unknown | No outcome recorded |
| Phase 2 | NCT00017225 | May 1997 → Feb 2002 | neuroblastoma | German Society for Pediatric Oncology and Hematology GPOH gGmbH | Completed | No outcome recorded |
| Phase 2 | NCT00001509 | Jul 1996 → May 2000 | Wilms tumor, neuroblastoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00001438 | Jun 1995 → Dec 2000 | HIV infectious disease, immunodeficiency disease, lymphoproliferative syndrome | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00002479 | Oct 1991 → Aug 2002 | lymphoma | Northwestern University | Completed | No outcome recorded |
| Phase 2/35 trials · 1 missed | ||||||
| Phase 2/3 | NCT07626398 | Jun 2026 → Jun 2028 expected | hemophagocytic syndrome | Beijing Anzhen Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07278908 | Dec 2025 → Dec 2028 expected | autoimmune thrombocytopenia | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05175508 | May 2021 → May 2022 | acute myeloid leukemia, myelodysplastic syndrome | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 2/3 | NCT00823901 | Feb 2009 → Oct 2010 | rosacea | Massachusetts General Hospital | Completed | Missed primary |
| Phase 2/3 | NCT00151242 | Jul 2004 → Aug 2011 | acute myeloid leukemia | University of Ulm | Completed | No outcome recorded |
| Phase 327 trials · 4 met primary | ||||||
| Phase 3 | NCT07597395 | May 2026 → Dec 2027 expected | autoimmune thrombocytopenia | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06706401 | Feb 2025 → Jan 2029 expected | hypopharynx cancer, larynx cancer, oropharynx cancer | Centre Leon Berard | Recruiting | No outcome recorded |
| Phase 3 | NCT06213987 | Feb → Jun 2024 | acanthosis nigricans, hyperpigmentation of the skin | Srinakharinwirot University | Completed | No outcome recorded |
| Phase 3 | NCT05654194 | Oct 2022 → Sep 2024 | acute myeloid leukemia | The First Affiliated Hospital of Soochow University | Completed | No outcome recorded |
| Phase 3 | NCT05438875 | Oct 2022 → Nov 2024 | autoimmune thrombocytopenic purpura | Peking University People's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05016349 | Aug → Oct 2021 | female breast carcinoma | Mahmoud Ramadan mohamed Elkazzaz | Unknown | No outcome recorded |
| Phase 3 | NCT03761784 | Dec 2018 → Dec 2019 | acne | Sol-Gel Technologies, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02688140 | Jun 2016 → Jan 2025 | acute promyelocytic leukemia | Technical University Dresden | Completed | Met primary |
| Phase 3 | NCT02965456 | Nov 2015 → Feb 2017 | acne | Bausch Health Americas, Inc. | Completed | Met primary |
| Phase 3 | NCT02932306 | Nov 2015 → Feb 2017 | acne | Bausch Health Americas, Inc. | Completed | Met primary |
| Phase 3 | NCT02339740 | Jul 2015 → Oct 2020 overdue | acute promyelocytic leukemia | Children's Oncology Group | Active not recruiting | Met primary |
| Phase 3 | NCT01882127 | Feb 2013 → Dec 2014 | autoimmune thrombocytopenic purpura | Shandong University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01237808 | Mar 2011 → Jul 2018 | acute myeloid leukemia | University of Ulm | Completed | No outcome recorded |
| Phase 3 | NCT01067274 | Apr 2010 → Apr 2016 | acute myeloid leukemia | Acute Leukemia French Association | Withdrawn | No outcome recorded |
| Phase 3 | NCT01041833 | Jan 2010 → Sep 2011 | non-small cell lung carcinoma | National Institute of Cancerology | Unknown | No outcome recorded |
| Phase 3 | NCT00891982 | Apr → Jun 2009 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 3 | NCT00866918 | Mar 2009 → Jun 2015 | acute promyelocytic leukemia | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00838812 | Mar 2009 → Jan 2010 | acne | Igefarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 3 | NCT01226303 | Jan 2009 → Jun 2017 | acute promyelocytic leukemia | Italian Association of Pediatric Hematology and Oncology | Unknown | No outcome recorded |
| Phase 3 | NCT00689117 | Apr 2008 → Apr 2009 | acne | Stiefel, a GSK Company | Completed | Mixed |
| Phase 3 | NCT00492856 | Jun 2007 → Dec 2013 | leukemia | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT00151255 | Jun 2004 → Jun 2009 | acute myeloid leukemia | University of Ulm | Completed | No outcome recorded |
| Phase 3 | NCT00005823 | Dec 1998 → Dec 2007 | leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease | Leukemia Research Fund | Completed | No outcome recorded |
| Phase 3 | NCT00005863 | Aug 1998 → Dec 2004 | myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, myeloid leukemia | Medical Research Council | Completed | No outcome recorded |
| Phase 3 | NCT00002701 | Oct 1995 → ? | leukemia | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | No outcome recorded |
| Phase 3 | NCT00002658 | Jan 1994 → ? | leukemia, neutropenia | Medical Research Council | Unknown | No outcome recorded |
| Phase 3 | NCT00599937 | Jan 1993 → Dec 1998 | acute promyelocytic leukemia | European Acute Promyelocytic Leukemia Group | Completed | No outcome recorded |
| Phase 420 trials · 1 met primary | ||||||
| Phase 4 | NCT07696806 | Jul 2026 → Jun 2027 expected | hyperpigmentation of the skin | Sameh Sarsik | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05002530 | Nov → Dec 2021 | anosmia | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 4 | NCT04548349 | Apr 2021 → Aug 2022 | acne | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04324411 | Apr 2020 → May 2023 | autoimmune disease | Peking Union Medical College Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT04096742 | Aug 2019 → Jul 2021 | — | Goldman, Butterwick, Fitzpatrick and Groff | Unknown | No outcome recorded |
| Phase 4 | NCT02020161 | Jun 2012 → Dec 2021 | acute promyelocytic leukemia | PETHEMA Foundation | Unknown | No outcome recorded |
| Phase 4 | NCT01448733 | Jul → Oct 2011 | acne | Zeichner, Joshua, M.D. | Unknown | No outcome recorded |
| Phase 4 | NCT01206348 | Sep 2010 → Jul 2011 | acne | Medicis Global Service Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01111994 | Nov 2009 → Mar 2010 | acne | Callender Center for Clinical Research | Unknown | No outcome recorded |
| Phase 4 | NCT00952523 | Jul → Oct 2009 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00919191 | Apr → May 2009 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00907257 | Feb → Sep 2009 | acne | Bausch Health Americas, Inc. | Completed | Met primary |
| Phase 4 | NCT00714714 | Jan → Feb 2008 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00841776 | Aug 2007 → Nov 2008 | acne | Stiefel, a GSK Company | Completed | No outcome recorded |
| Phase 4 | NCT00504764 | Jul 2007 → Oct 2014 | acute promyelocytic leukemia | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 4 | NCT00472966 | Nov 2006 → Apr 2007 | hyperpigmentation of the skin | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT00469183 | May 2006 → Apr 2007 | hyperpigmentation of the skin | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT00408278 | Jul 2005 → Apr 2012 | acute promyelocytic leukemia | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 4 | NCT00240513 | Aug 2004 → Dec 2006 | acne | Derm Research @ 888 Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00465933 | Mar 1999 → Aug 2007 | acute promyelocytic leukemia | PETHEMA Foundation | Completed | No outcome recorded |
| Phase not applicable12 trials · 1 met primary | ||||||
| — | NCT07187505 | Jul 2025 → Jul 2027 expected | acute promyelocytic leukemia | Anhui Medical University | Active not recruiting | No outcome recorded |
| — | NCT06780644 | Feb → May 2025 overdue | hyperpigmentation of the skin | Indonesia University | Not yet recruiting | No outcome recorded |
| — | NCT06841952 | Feb 2025 → Dec 2028 expected | acute myeloid leukemia | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| — | NCT06371274 | Oct 2024 → Apr 2026 overdue | triple-negative breast carcinoma | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| — | NCT06516419 | Feb 2024 → Mar 2025 overdue | hyperpigmentation of the skin | Indonesia University | Recruiting | No outcome recorded |
| — | NCT06008327 | Aug 2022 → Jun 2023 | acanthosis nigricans | Jinnah Postgraduate Medical Centre | Completed | No outcome recorded |
| — | NCT05004909 | Sep → Dec 2021 | hyperpigmentation of the skin | Indonesia University | Unknown | No outcome recorded |
| — | NCT03933774 | Apr → Nov 2019 | vitiligo | The Catholic University of Korea | Completed | Met primary |
| — | NCT02551718 | Sep 2015 → Jun 2020 | acute leukemia of ambiguous lineage, acute lymphoblastic leukemia | University of Washington | Completed | No outcome recorded |
| — | NCT01349556 | May 2011 → Mar 2014 | drug allergy | Johns Hopkins University | Withdrawn | No outcome recorded |
| — | NCT00003598 | Jan 1999 → Mar 2001 | cervical cancer, precancerous condition | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| — | NCT01064557 | Oct 1993 → Dec 2020 | leukemia | GIMEMA Foundation | Unknown | No outcome recorded |
| Comparator or background therapy62 trials | ||||||
| Phase 0 | NCT03433378 Comparator | Aug 2017 → Jan 2018 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04059523 Comparator | Jun 2019 → Feb 2020 | acne | Sol-Gel Technologies, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04206631 Comparator | Apr → Sep 2015 | acne | Indonesia University | Completed | No outcome recorded |
| Phase 1 | NCT01161550 Background | Nov 2010 → Aug 2011 | acute myeloid leukemia | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00604032 Comparator | Jan 2008 | — | Coria Laboratories, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00195156 Background | Jul 2003 → ? | high grade malignant neoplasm | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 1/2 | NCT02712905 Background | May 2016 → Apr 2022 | hematopoietic and lymphoid system neoplasm | Incyte Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02717884 Background | May 2015 → Dec 2020 | acute myeloid leukemia, myelodysplastic syndrome | Michael Luebbert | Unknown | No outcome recorded |
| Phase 1/2 | NCT00919555 Comparator | Jun 2008 → Nov 2009 | amyotrophic lateral sclerosis | Phoenix Neurological Associates, LTD | Completed | No outcome recorded |
| Phase 2 | NCT07366229 Comparator | Dec 2025 → Mar 2026 overdue | acne | Shenzhen People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05461755 Comparator | Nov 2022 → Jul 2023 | dermis disorder | Merete Haedersdal | Completed | No outcome recorded |
| Phase 2 | NCT06013540 Background | Aug → Dec 2022 | hyperpigmentation of the skin | Jinnah Postgraduate Medical Centre | Unknown | No outcome recorded |
| Phase 2 | NCT04687176 Background | Jan 2021 → Dec 2025 overdue | acute promyelocytic leukemia | The University of Hong Kong | Recruiting | No outcome recorded |
| Phase 2 | NCT04396067 Comparator | Oct 2020 | COVID-19 | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 2 | NCT04080869 Comparator | Jan → Aug 2020 | acne | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT03624270 Background | Aug 2018 → Sep 2023 | acute promyelocytic leukemia | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 2 | NCT02278861 Comparator | Nov 2011 → Apr 2014 | actinic keratosis | Federal University of Goiás | Completed | No outcome recorded |
| Phase 2 | NCT01283464 Comparator | Nov 2010 → Dec 2011 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT00842907 Comparator | May → Dec 2009 | radiation-induced disorder | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 2 | NCT01085279 Comparator | Mar 2009 → Feb 2010 | skin pigmentation disorder | Netherlands Institute for Pigment Disorders | Completed | No outcome recorded |
| Phase 2 | NCT00621218 Comparator | Feb → Apr 2008 | rosacea | Coria Laboratories, Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00514293 Background | Jan 2007 → Dec 2011 | lung cancer | Raghu Nandan, M.D., Inc | Unknown | No outcome recorded |
| Phase 2 | NCT00276601 Background | Oct 2004 → Dec 2007 | leukemia | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00100906 Comparator | Aug 2004 → Jun 2006 | kidney cancer | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00136461 Background | May 1997 → Aug 2000 | acute myeloid leukemia, myelodysplastic syndrome | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT07084116 Comparator | Jul 2025 → May 2026 | purpura, skin atrophy | James Thomas Pathoulas | Completed | No outcome recorded |
| Phase 2/3 | NCT06787222 Comparator | Nov 2024 → Aug 2025 overdue | acne | Hasanuddin University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT00717652 Background | Jul 2008 | hyperpigmentation of the skin | Azidus Brasil | Suspended | No outcome recorded |
| Phase 3 | NCT07504458 Background | Jun 2026 → Mar 2027 expected | acute promyelocytic leukemia | Quetzal Therapeutics | Recruiting | No outcome recorded |
| Phase 3 | NCT07296445 Background | Jan 2026 → Jun 2027 expected | acute myeloid leukemia, t(15;17)(q24;q21), acute promyelocytic leukemia | SDK Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07503730 Background | Jun 2025 → Jun 2028 expected | acute promyelocytic leukemia | First Affiliated Hospital Xi'an Jiaotong University | Recruiting | No outcome recorded |
| Phase 3 | NCT06447480 Comparator | Apr 2025 → Sep 2027 expected | acne | Centre Hospitalier Universitaire de Nice | Recruiting | No outcome recorded |
| Phase 3 | NCT02899169 Background | Sep 2016 → Sep 2022 | acute promyelocytic leukemia | First Affiliated Hospital Xi'an Jiaotong University | Unknown | Met primary |
| Phase 3 | NCT01406080 Comparator | Jan 2013 → Nov 2015 | hyperpigmentation of the skin, radiation-induced disorder | Galderma Brasil Ltda. | Completed | No outcome recorded |
| Phase 3 | NCT00893399 Background | May 2010 → Sep 2021 | acute myeloid leukemia | University of Ulm | Completed | Missed primary |
| Phase 3 | NCT01125930 Comparator | May 2010 → Jan 2013 | rosacea | Lisa E. Maier | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00647556 Comparator | Apr 2008 → Jan 2010 | hyperpigmentation of the skin | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT00482833 Background | Aug 2007 → Sep 2012 | leukemia | GIMEMA Foundation | Completed | Met primary |
| Phase 3 | NCT00962767 Comparator | May 2002 → Dec 2007 | acute myeloid leukemia | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00003934 Background | Jun 1999 → Nov 2006 | acute myeloid leukemia, t(15;17)(q24;q21), acute promyelocytic leukemia, childhood acute myeloid leukemia | National Cancer Institute (NCI) | Completed | Met primary |
| Phase 3 | NCT00007631 Comparator | Mar 1998 → Nov 2004 | basal cell carcinoma, skin neoplasm, squamous cell carcinoma | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 4 | NCT07012811 Comparator | Feb 2024 → Mar 2025 | skin disorder caused by infection | Latakia University | Completed | No outcome recorded |
| Phase 4 | NCT02731105 Comparator | Feb 2015 → Feb 2017 | acne | GWT-TUD GmbH | Completed | No outcome recorded |
| Phase 4 | NCT01987297 Background | Jun 2012 → Dec 2020 | acute promyelocytic leukemia | Shanghai Jiao Tong University School of Medicine | Unknown | Met primary |
| Phase 4 | NCT01522456 Comparator | Apr → May 2012 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT02200978 Background | Sep 2011 → Oct 2021 | acute promyelocytic leukemia | South China Children's Leukemia Group | Completed | No outcome recorded |
| Phase 4 | NCT01422785 Comparator | Jul → Dec 2011 | acne | Zeichner, Joshua, M.D. | Unknown | No outcome recorded |
| Phase 4 | NCT01313728 Comparator | Dec 2010 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01149876 Comparator | Jun 2010 → Dec 2011 | hyperpigmentation of the skin | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00939133 Comparator | Jul 2009 → Dec 2010 | acne | Dermatrials Research | Completed | No outcome recorded |
| Phase 4 | NCT01047189 Comparator | Mar → Oct 2009 | acne | Wake Forest University | Completed | No outcome recorded |
| Phase 4 | NCT01027793 Comparator | Mar 2009 → Aug 2010 | striae distensae, familial | Hexsel Dermatology Clinic | Completed | No outcome recorded |
| Phase 4 | NCT00835198 Comparator | Dec 2008 → Aug 2009 | acne | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00669071 Comparator | Jan → Oct 2008 | hyperpigmentation of the skin | Galderma R&D | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT07485777 Comparator | Jul → Dec 2026 expected | hyperpigmentation of the skin | Foundation University Islamabad | Not yet recruiting | No outcome recorded |
| — | NCT07345507 Comparator | Feb → Aug 2025 | hyperpigmentation of the skin | Jinnah Postgraduate Medical Centre | Completed | No outcome recorded |
| — | NCT06181838 Comparator | Aug → Nov 2023 | acne | Indonesia University | Unknown | No outcome recorded |
| — | NCT05710068 Background | Dec 2021 → Aug 2022 | hyperpigmentation of the skin | Ajou University School of Medicine | Completed | No outcome recorded |
| — | NCT04835259 Comparator | Apr 2021 → Apr 2022 | — | Sohag University | Unknown | No outcome recorded |
| — | NCT02704507 Background | Jun 2015 → Jan 2016 | acne | Carilion Clinic | Unknown | No outcome recorded |
| — | NCT01335581 Background | Apr 2011 → Mar 2012 | mixed dermis disorder | ConBio, a Cynosure Company | Completed | No outcome recorded |
| — | NCT00974480 Comparator | Sep 2009 → Jul 2010 | skin atrophy | Cosmetique Active International | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Alembic Pharmaceuticals Ltd. | Regulatory 12th June, 2026 Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tretinoin Cream USP, 0.05%. |
| 2024-05-01 | Alembic Pharmaceuticals Ltd. | Regulatory Press Release USFDA Products Approval dated 9th May, 2024 alembicpharmaceuticals.com ↗
This is to inform the exchanges that the Company has received various US Food & Drug Administration (USFDA) (Tentative or Final) Product Approvals. |
| 2024-04-26 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from USFDA for Tretinoin Cream USP, 0.1% zyduslife.com ↗
Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) to market Tretinoin Cream USP, 0.1%, (USRLD: Retin-A Cream, 0.1%). |
| 2021-07-27 | Galderma R&D | Regulatory Sol-Gel Technologies Announces FDA Approval of TWYNEO® galderma.com ↗
TWYNEO®, a once-daily cream treatment for acne vulgaris, is the first FDA-approved fixed-dose combination of tretinoin and benzoyl peroxide |
| 2018-01-15 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces U.S. FDA Approval of TRISENOX® (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic Leukemia tevapharm.com ↗
This label expansion represents an important benefit as TRISENOX is now an FDA-approved first line treatment option for patients with acute promyelocytic leukemia. |
| 2017-10-05 | Teva Branded Pharmaceutical Products R&D, Inc. | Results Teva Announces tomy’s Award Winner at Oncology Satellite Symposium During the 7th International Symposium on Acute Promyelocytic Leukemia (APL) in Rome, Italy tevapharm.com ↗
The research found that patients treated with all-trans retinoic acid (ATRA) plus anthracycline-based regimen showed better outcomes than patients who received other strategies, such as ATRA alone, chemotherapy alone or best supportive care. |
| 2017-09-12 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Receives FDA Priority Review for First Line Use of TRISENOX® (arsenic trioxide) in Patients with Low to Intermediate Risk Acute Promyelocytic Leukemia (APL) tevapharm.com ↗
The FDA has accepted the sNDA for priority review with regulatory action expected in the first quarter of 2018. |
| 2002-05-15 | Heron Therapeutics | Regulatory Second Formulation of RETIN-A MICRO Approved for U.S. Market; Launch Anticipated in June 2002; Potential to Significantly Increase A.P. Pharma's Royalties herontx.com ↗ |
| 2001-07-23 | Heron Therapeutics | Regulatory Retin-A Micro Receives Marketing Clearance in Canada; Johnson & Johnson Canada to Market Prescription Acne Treatment Containing Microsponge Systems in Canada herontx.com ↗
A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that Canadian drug regulatory authorities have granted marketing clearance for Retin-A Micro(R) (tretinoin gel) microsphere, 0.1% for the treatment of acne. |
All press releases naming this drug 13 releases
Evidence & citations 28 cited values
Every value below carries the sentence it was read from. 245 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tretinoin | “METHODS: This 16-week, two-center, investigator-blinded, randomized, parallel-group study evaluated the antimicrobial efficacy of clindamycin phosphate 1%/benzoyl peroxide 5%...” PMID 20214175 ↗ Feb 2010118“Open-Label study designed to assess the safety and plasma PK of tretinoin and relevant metabolites after topical dermal application of IDP-121 lotion in subjects with moderate...” NCT02849860 ↗ “This study was a prospective, two-arm, multicenter clinical trial to evaluate the efficacy and safety of tretinoin capsules combined with azacitidine and venetoclax in the...” NCT06841952 ↗ “Apply triple combination cream (Refaquin) containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around...” NCT06516419 ↗ “Apply triple combination cream containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around the eyes, 1...” NCT06780644 ↗ “Participants received modified Kligman's formula consisting of hydroquinone 4%, tretinoin 0.05%, and mometasone furoate 0.1% immediately after standardized microneedling with a...” NCT07696806 ↗ “HF1K16 is an investigational pegylated liposome formulation of tretinoin for injection for the treatment of solid tumors through targeting myeloid derived suppressor cells (MDSCs).” NCT05386823 ↗ “IDP-121 lotion (tretinoin 0.05 percent [%]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.” NCT02965456 ↗ “IDP-121 lotion (tretinoin 0.05 percent [%]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.” NCT02932306 ↗ “Topical application of a retinoid (tretinoin 0.05%) cream once daily at night for 6 months (Acretin 0.05% cream Jamjoom pharmaceuticals, Egypt)” NCT04835259 ↗ “Kligman's regimen - a combination of hydroquinone, tretinoin, and fluocinolone acetonide - remains the gold standard for treatment” NCT07485777 ↗ |
| Known as | Acretin 0.05% cream | “Topical application of a retinoid (tretinoin 0.05%) cream once daily at night for 6 months (Acretin 0.05% cream Jamjoom pharmaceuticals, Egypt)” NCT04835259 ↗ |
| Known as | all-trans retinoic acid | “Recent laboratory data have shown that all-trans-retinoic acid, a derivative of vitamin A, can regenerate alveoli in adult rats with elastase induced emphysema (Massaro, GD and...” NCT00000621 ↗101“Acute promyelocytic leukemia (APL) is highly curable with the combination of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy (CT), but very long-term...” PMID 20018913 ↗ Dec 2009 “HF1K16 is an investigational pegylated liposome formulation of All-Trans Retinoic Acid (ATRA) for the induction of remission in patients with acute promyelocytic leukemia (APL)...” NCT05388487 ↗ “Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations including, but not limited to: Lenvatinib,...” NCT05553782 ↗ “This study is a prospective, double-blind, multicenter, randomized controlled phase II clinical trial of tislelizumab combined with chemotherapy and all trans retinoic acid in...” NCT06703047 ↗ “PRIMARY OBJECTIVES: I. Assess whether a combination of all-trans retinoic acid (ATRA [tretinoin]), and arsenic trioxide (ATO) can produce long-term event-free survival in...” NCT01409161 ↗ “The purpose of this research study is to learn if adding all-trans retinoic acid (tretinoin) to conventional treatment of Anti- Neutrophil Cytoplasmic Autoantibodies (ANCA)...” NCT01275274 ↗ “Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and...” NCT01041833 ↗ “Patients aged ⩾60 years reported to the PETHEMA registry and were treated with all-trans retinoic acid (ATRA) plus anthracycline-based regimens according to three consecutive...” PMID 28584252 ↗ Jun 2017 “a novel biomodulatory treatment regimen consisting of low-dose azacitidine (AZA) in combination with PPARγ agonist pioglitazone (PGZ) and all-trans retinoic acid (ATRA) induced...” PMID 30542286 ↗ Nov 2018 “A Multi-Center Phase 2 Study of Daratumumab With Pomalidomide and Dexamethasone in Combination With All-Transretinoic Acid in Patients With Multiple Myeloma Previously Exposed...” NCT04700176 ↗ |
| Known as | All-Trans Retonoic Acid | “Decitabine and All-Trans Retonoic Acid (Tretinoin)” NCT00382200 ↗ |
| Known as | Altreno | “tretinoin 0.05% lotion (Altreno)” NCT04096742 ↗ |
| Known as | ATRA | “This is an open-label clinical trial study that aims to evaluate the efficacy (eg. Complete response, Overall Survival, Progression Free Survival) and adverse effects of...” NCT06158412 ↗75“HF1K16 is an investigational pegylated liposome formulation of All-Trans Retinoic Acid (ATRA) for the induction of remission in patients with acute promyelocytic leukemia (APL)...” NCT05388487 ↗ “Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations including, but not limited to: Lenvatinib,...” NCT05553782 ↗ “This is a prospective, open-label, randomized controlled clinical intervention study to evaluate the efficacy and safety of all-trans retinoic acid (ATRA) in treating patients...” NCT04433169 ↗ “PRIMARY OBJECTIVES: I. Assess whether a combination of all-trans retinoic acid (ATRA [tretinoin]), and arsenic trioxide (ATO) can produce long-term event-free survival in...” NCT01409161 ↗ “Retinoid treatment arms were all-trans retinoic acid (ATRA trademark, Roche Laboratories, Inc.) at two different doses and 13-cis retinoic acid (cRA, Roche Laboratories, Inc.),...” NCT00000621 ↗ “Induction All-trans retinoic acid (ATRA), 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1.” NCT00482833 ↗ “All-Trans Retinoic Acid (ATRA) is an oxidative metabolite of retinol (vitamin A) and plays an important role in the regulation of cellular proliferation and differentiation.” NCT06536413 ↗ “All-trans Retinoic Acid (ATRA)-Based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment of High-risk Relapsed/Refractory B-NHL Ineligible for High-dose Chemotherapy” NCT06646666 ↗ “All-Trans Retinoic Acid (ATRA) is administered orally, twice daily, as part of standard induction and consolidation therapy for acute promyelocytic leukemia.” NCT07187505 ↗ “In Acute Promyelocytic Leukemia (APL, AML M3), all-trans-retinoic-acid (ATRA; Tretinoin) induces differentiation and subsequently clinical remission.” NCT02261779 ↗ |
| Known as | ATRA-IV | “liposome encapsulated all-trans retinoic acid (ATRA-IV)” NCT00195156 ↗ |
| Known as | Atralin | “We want to find out if Atralin (tretinoin 0.05%) Gel used for up to 46 weeks will improve erythematotelangiectatic rosacea (ETR).” NCT01125930 ↗3“A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea” NCT00621218 ↗ “Atralin (tretinoin) gel, 0.05%” NCT00603772 ↗ “Atralin (tretinoin) Gel, 0.05%” NCT00604032 ↗ |
| Known as | E-ATRA | “Encapsulated Benzoyl Peroxide (E-BPO) and Encapsulated Tretinoin (E-ATRA) Cream, (E-BPO/E-ATRA Cream)” NCT03761784 ↗ |
| Known as | IDP-121 | “IDP-121 lotion (tretinoin 0.05 percent [%]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.” NCT02932306 ↗ |
| Known as | IDP-121 Lotion | “IDP-121 lotion (tretinoin 0.05 percent [%]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.” NCT02965456 ↗ |
| Known as | liposomal tretinoin | “PURPOSE: Phase II trial to study the effectiveness of liposomal tretinoin plus interferon alfa in treating patients who have metastatic kidney cancer.” NCT00003656 ↗1“Phase II Study of ATRAGEN (Liposomal Tretinoin) in Patients With Relapsed or Refractory Hodgkin's Disease” NCT00005969 ↗ |
| Known as | NSC-122758 | “Tretinoin, All-trans-Retinoic Acid, TRA, NSC-122758.” NCT00002479 ↗ |
| Known as | RETIN-A | “RETIN-A® (Tretinoin) Cream (Valeant)” NCT03427554 ↗ |
| Known as | RETIN-A MICRO | “RETIN-A MICRO ® (Tretinoin) Gel Microsphere, 0.04% (Reference Listed Drug)” NCT07469228 ↗2“RETIN-A MICRO (Tretinoin Gel) Microsphere, 0.04% in a Pump Dispenser” NCT00907257 ↗ “RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1% (Valeant)” NCT04883736 ↗ |
| Known as | retinoic acid | “Tretinoin, also called all-trans retinoic acid (ATRA), retinoic acid, and vitamin A acid is in a class of medications called retinoids.” NCT07848568 ↗1“Topical tretinoin (retinoic acid) has been well established to be effective for skin pigmentary disorders including melasma.” NCT03933774 ↗ |
| Known as | TRA | “Tretinoin, All-trans-Retinoic Acid, TRA, NSC-122758.” NCT00002479 ↗ |
| Known as | Trans-Retinoic acid | “This is an open-label clinical trial study that aims to evaluate the efficacy (eg. Complete response, Overall Survival, Progression Free Survival) and adverse effects of...” NCT06158412 ↗ |
| Known as | tretinoin liposome | “Patients receive tretinoin liposome IV over 30 minutes once weekly and interferon alfa-2b subcutaneously on five consecutive days (M-F) for 8 weeks.” NCT00003656 ↗ |
| Known as | VESANOID | “The first medicine is tretinoin (also called all-trans retinoic acid, ATRA, or Vesanoid).” NCT01404949 ↗ |
| Known as | vitamin A acid | “Tretinoin, also called all-trans retinoic acid (ATRA), retinoic acid, and vitamin A acid is in a class of medications called retinoids.” NCT07848568 ↗ |
| Action | Inhibit | “inhibits HPV E6/E7 gene expression” NCT00003598 ↗ |
| Modality | Other / unclassified | “ATRA is a biological agent that has been shown to induce cell differentiation in leukemia cell lines” NCT00326170 ↗ |
| Route | Oral | “oral tretinoin (ATRA)” NCT00002701 ↗ |
| Target | HOXA3 | “ATRA modulates HOX activity (i.e. decreased expression of HOXA3, HOXA4 and HOXA5 and their regulator PBX3)” PMID 28877686 ↗ Sep 2017 |
| Target | HOXA4 | “ATRA modulates HOX activity (i.e. decreased expression of HOXA3, HOXA4 and HOXA5 and their regulator PBX3)” PMID 28877686 ↗ Sep 2017 |
| Target | HOXA5 | “ATRA modulates HOX activity (i.e. decreased expression of HOXA3, HOXA4 and HOXA5 and their regulator PBX3)” PMID 28877686 ↗ Sep 2017 |
| Target | PBX3 | “ATRA modulates HOX activity (i.e. decreased expression of HOXA3, HOXA4 and HOXA5 and their regulator PBX3)” PMID 28877686 ↗ Sep 2017 |